INHIBIKASE THERAPEUTICS INC

$IKT
Institutional coverage

87 13F filers hold $IKT.

13F holders
87
Insider buys · 90d
0
Congress · 90d
0

Smart Money · top-200 alpha cohort

3 holders · Q1 2026

$IKT is held by 3 managers from the Top-Performer cohort as of Q1 2026. Position weights range from 0.66% to 0.74%, with an average of 0.70% of portfolio. Largest holder: Soleus Capital Management, L.P. at 0.74%. A weekly Smart-Money commentary for this ticker has not been generated yet this batch — the table below shows the full cohort positioning.

Smart Money shows holdings from our Top-Performer cohort — the 200 highest-alpha manager_13f funds in our universe. Position weight (current quarter) and QoQ delta versus prior quarter. α is the manager's annual alpha vs benchmark.

Institutional holders

Top 10 of 87 · Source: 13F-HR
01
Rempart Asset Management Inc.
5.19% of portfolio
13,018,965 sh
02
Atlantic Edge Private Wealth Management, LLC
10,945,880 sh
03
Certuity, LLC
0.74% of portfolio
10,875,000 sh
04
Chico Wealth RIA
0.66% of portfolio
6,606,572 sh
05
Fairmount Funds Management LLC
0.89% of portfolio
6,125,000 sh
06
Palisades Hudson Asset Management, L.P.
0.04% of portfolio
5,938,276 sh
07
GSG Advisors LLC
0.27% of portfolio
5,850,000 sh
08
Vernal Point Advisors, LLC
0.52% of portfolio
5,397,488 sh
09
Strategic Investment Solutions, Inc.
1.18% of portfolio
3,863,445 sh
10
Evergreen Capital Management LLC
2,928,077 sh
See all 87 13F holders · Pro →

Insider activity · last 90 days

1 transactions · 1 filers
21 Nov 2025
Sands Capital Life Sciences Pulse Fund II, L.P.
▲ BOUGHT
2,068,965
$1.45
P

Transaction codes: P open-market purchase · S sale · M option exercise · A grant · F tax-withhold sale. Insider names link to each individual's expert page.

Congress trades · last 90 days

No Congress trades

No STOCK Act filings reference $IKT in the recent window.

Source data: SEC EDGAR · 13F-HR · Form 4 · U.S. House Clerk PTR (disclosures-clerk.house.gov) · Senate eFD (senate.gov) · Last refreshed 10:26 UTC.